2. Signaling Pathways
  3. Autophagy
  4. Mitophagy
  5. Mitophagy Inducer

Mitophagy Inducer

Mitophagy Inducers (6):

Cat. No. Product Name Effect Purity
  • HY-160019
    MTX115325
    		Inducer 99.08%
    MTX115325 (Example 1) is an orally active, brain-penetrating USP30 inhibitor (IC50=12 nM) with neuroprotective activity. MTX115325 increases ubiquitination (EC50=32 nM) of the mitochondrial outer membrane protein TOM20 (a USP30 substrate), increasing mitophagy. MTX115325 prevents dopaminergic neuron loss and preserves striatal dopamine.
  • HY-157304
    ATTECs Degrader 1
    		Inducer
    ATTECs Degrader 1 (Compound MT1) is an ATTECs compound. ATTECs Degrader 1 can bind to both the outer mitochondrial membrane protein (TSPO) and the autophagosome protein LC3B. ATTECs Degrader 1 enhances the degradation of damaged mitochondria by autophagosomes and subsequent autophagic degradation.
  • HY-153089
    GSK3-IN-3
    		Inducer 98.80%
    GSK3-IN-3 is a mitophagy inducer, inducing Parkin-dependent mitophagy. GSK3-IN-3 is also a GSK-3 inhibitor with an IC50 value of 3.01 μM. GSK3-IN-3 is non-ATP nor substrate competitive and is neuroprotective against 6-OHDA.
  • HY-153797
    Dox-btn2
    		Inducer
    Dox-btn2 is a biotinylated derivative of Doxorubicin (HY-15142A), with a biotin label at the point of conjugation to doxorubicin at 3'-NH2. Dox-btn2 can be used for cell imaging. While Doxorubicin is mainly accumulated in the nucleus, while Dox-btn2 is mainly located in the cytoplasm.
  • HY-15142A
    Doxorubicin
    		Inducer
    Doxorubicin (Hydroxydaunorubicin), a broad-spectrum anthracycline antibiotic with cytotoxic properties, is an anti-cancer chemotherapy agent. Doxorubicin has fluorescence properties. Doxorubicin inhibits topoisomerase II with an IC50 of 2.67 μM, thus stopping DNA replication. Doxorubicin reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin induces apoptosis and autophagy. Doxorubicin inhibits human DNA topoisomerase I with an IC50 of 0.8 μM.
  • HY-162325
    WJ-39
    		Inducer
    WJ-39 is an orally active aldose reductase (AR) inhibitor. WJ-39 improves tubular damage in diabetic nephropathy rats by activating PINK1/Parkin signaling, promoting mitophagy, and attenuating apoptosis.